Arterys, a San Francisco-based healthcare company focused on cloud-based medical imaging technology, announced Thursday, Feb. 15, that it has received FDA clearance for its Arterys Oncology AI suite. The company says this is the first time the FDA has cleared an oncology imaging suite that uses deep learning technology.

This new software, which represents the company’s fifth FDA clearance, is designed to use deep learning to help radiologists “confirm, evaluate, quantify and report on the absence or presence of” various tumors or potential cancers. The initial launch of Oncology AI is focused on liver MRI and CT exams and lung CT exams.

“The evaluation of primary and metastatic disease in the lung and liver are among the most valuable contributions of radiologists to the care of patients with cancer,” Arterys co-founder Albert Hsiao, MD, PhD, said in a prepared statement. “We desperately need more efficient technology to automatically track lung and liver lesions to further improve diagnosis, assess response to treatment, and automate reporting with standardized terminology including Lung-RADS and LI-RADS. The Oncology Lung AI and Liver AI products are designed to maximize efficiency and accuracy of the radiologist read and will power next-generation radiology interpretation.”

The software runs on the Arterys Medical Imaging Cloud AI platform.